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were linearly related to PVR (Table)however the highest correlation with the severity of
PVR was seen with the maximum diameter (r20.48, p0.001), mean diam-
eter(r20.47, p0.0001), average diameter (r20.48, p0.0001) or the annular area
(r20.48, p0.0001).
Conclusions: This study demonstrates that 3DE measurements of the aortic annulus are
feasible and are better predictors of PVR after TAVR than 2D sagittal diameter and should
be incorporated into the algorithm for balloon-expandable transcatheter valve sizing.
Comparison of 2DE and 3DE Measurements
Cover Index NoPD (n23) PD (n35) p-value
r2 for linear
measure
2DE Sagittal 10.14 4.02 6.89 3.24 0.002 0.26
(p  0.001)
3DE Minimum 16.19 6.39 10.88 4.91 0.001 0.36
(p0.0001)
3DE Maximum 8.67 7.87 -2.74 6.50  0.001 0.48
(p0.0001)
3DE Mean 12.44 6.65 4.07 4.71  0.001 0.47
(p0.0001)
3DE Average 11.50 6.11 2.68 4.93  0.001 0.48
(p0.0001)
3DE Area 23.09 10.32 7.91 9.14  0.001 0.48
(p0.0001)
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Background: Despite excellent outcome after transcatheter aortic valve implantation
(TAVI), paravalvular leaks may occur. Objective of this study was to evaluate annulus
sizing by 3-D computed tomography (CT) for prediction of paravalvular leaks after TAVI,
and to compare CT with transesophageal (TEE) and intracardiac echocardiography (ICE).
Methods: In 88 patients (mean, 83yrs) with severe aortic stenosis who underwent TAVI,
transesophageal (TEE), intracardiac echocardiography (ICE) and ECG-gated CT-
Angiography were performed before device implantation. Two-(ML/AP), three-annulus
diameter (RC/LC/NC) and the annulus area were measured on CTA. “Undersizing” was
defined as CT annulus–prosthetic heart valve (PHV) size; “annulus eccentricity” as
AP/ML-annulus diameter ratio. Post-procedural echocardiography was performed imme-
diately after, and at 1, 3,6, 12 and 24 month after the procedure and severity of
paravalvular leaks graded.
Results: Of 88 implanted prosthetic heart valves (PHV) 22 (25%) had none, 46 (52.3%)
mild, 11 (12.5%) mild-to-moderate, 9 (10.2%) moderate or moderate-to-severe, and 0%
severe leaks. Both TEE and ICE measured smaller mean annulus diameters than CT
(mean:-2,84mm and -2.19mm, resp., p0.01). Overall, 53% of PHV were undersized, in
only 3/22 (14%) patients with no leaks and in 35/66 (53%) with leaks. Undersizing was
higher in those with leaks as compared to those without (1mm vs 0.2mm, p0.01). No
difference between mild and moderate-to-severe (1mm vs. 1.2mm, p0.64) leaks were
found for the mean of 3-annulus diameters. The annulus area undersizing was higher in
patients with leaks than in those without (0.44cm2 vs 0.14cm2, p0.05), however the
annulus eccentricity index was not different (0.82 vs. 0.82, p0.06). If applying the 3-
instead of 2-diameter annular CT measurements, 4 (5%) patients without leaks and 2 (2%)
with leaks were reclassified as not-undersized and undersized, respectively.
Conclusions: PHV undersizing relative to CT annulus dimensions is associated with
paravalvular leaks after TAVI, but not annulus eccentricity. Three-diameter annulus
sizing by CT may be more accurate than the two-diameter method.
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Background: To develop computed tomography (CT) sizing guidelines for transcatheter
aortic valve replacement (TAVR). CT annular measurements are predictive of paraval-
vular regurgitation post TAVR; a predictor of mortality and morbidity.
Methods: The Vancouver CT sizing guidelines aim to ensure routine transcatheter heart
valve (THV) over sizing of the aortic annulus (range:1-20%, target 10-15%). Percentage
of over sizing is defined as (THV external area/annular area-1) x 100. 120 consecutive
patients underwent CT prior to TAVR with balloon expandable valves using transesoph-
ageal echocardiography (TEE) sizing recommendations. The Vancouver CT sizing
guidelines recommended prosthesis size was compared to the actual size implanted.
Results: As compared to TEE sizing recommendations, the Vancouver CT sizing
guidelines recommended a larger valve in 33.3% (40/120), no change in valve size in
55.8% (67/120) and a smaller valve in 10.8%(13/120). In patients where CT guidelines
would have recommended a larger valve, the incidence of at least moderate paravalvular
regurgitation was 25% (10/40), compared to only 4.5% (3/67, p0.01) when both TEE
and CT guidelines were in agreement. Traditional TEE sizing methods resulted in
33.3%(40/120) of valves being under sized (THV areaCT annular area) with a mean
annular over sizing of 9.417.4% (range: -21.5 to 65.9%) without annular rupture. In
contrast, the Vancouver CT sizing guidelines results in mean annular over sizing of
13.98.0% (range: 1.3-29.8%).
Conclusions: The Vancouver CT sizing guidelines enable standardized moderate over
expansion of the annulus that is likely to result in significantly lower rates of paravalvular
regurgitation.
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Background: Transcatheter aortic valve-in-valve (VIV) implantation is an emerging
therapeutic alternative for patients with failed surgical bioprosthesis and may obviate the
need for a redo surgery. We aimed to evaluate the clinical results of this technique using
a large worldwide registry.
Methods: The registry included 416 patients with degenerated aortic bioprosthetic valves
(age 77.7  9.7 years; 55.3% men) from 54 cardiac centers. The mode of failure was
stenosis (n168, 40.4%), regurgitation (n125, 30%), and combined stenosis and
regurgitation (n123, 29.6%). Implanted devices were Edwards SAPIEN (n225),
CoreValve (n190) and Melody (n1).
Results: Adverse procedural outcomes included 11.1% device malposition and 1.9%
ostial coronary obstruction. Post-procedure, valve maximum / mean gradients were 28.5 
14.3 mmHg / 16.1  9.0, respectively. Independent predictors for high post-
procedural gradients (mean 20 mmHg) were baseline bioprosthesis stenosis [vs.
regurgitation, odds ratio (OR), 6.33, p  0.001)] and the use of the Edwards SAPIEN
device (OR 2.1, p 0.008). At 30-day follow-up, all-cause mortality was 7.8% and
87.5% of patients were at New York Heart Association functional class I/II. One-year
survival was 82.6%. The strongest independent predictor for 1-year mortality post
VIV was baseline bioprosthesis stenosis (vs. regurgitation, OR 3.7, p0.003).
Conclusions: The VIV procedure is clinically effective in most patients, with 1-year
results comparable with other TAVR cohorts. Baseline bioprosthetic stenosis is the
strongest predictor for both elevated post-procedural gradients and 1-year mortality.
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Background: A novel, innovative transapical aortic valve implantation (TA-TAVI)
system completed enrollment (n90) in two pre-market studies. The TA device received
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